Ampersand Capital Partners-backed New England Peptide, that designs and manufactures peptide and antibody solutions for drug, vaccine and diagnostic development organizations, completed the merger with Peptides International, a provider of catalog and custom peptide products. Financial terms were not disclosed. "New England Peptide is excited to announce that in our 20th year as a custom peptide synthesis company, we have merged with Peptides International. This transaction adds meaningful scale, capabilities, customer relationships, and a similarly strong market reputation to what we have built at New England Peptide," Sam Massoni, New England Peptide CEO.